Art

J-GLOBAL ID：201102211990070343   Reference number：11A0809644

Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial -

心房細動患者におけるダビガトラン対ワルファリンの有効性と安全性 RE-LYトライアルにおける日本人集団のサブ解析

Author (7)： HORI Masatsugu (Osaka Medical Center for Cancer and Cardiovascular Diseases) ,  CONNOLLY Stuart J. (Population Health Res. Inst., McMaster Univ. and Hamilton Health Sciences) ,  EZEKOWITZ Michael D. (Lankenau Inst. for Medical Res. and the Heart Center) ,  REILLY Paul A. (Boehringer Ingelheim Pharmaceuticals Inc) ,  YUSUF Salim (Population Health Res. Inst., McMaster Univ. and Hamilton Health Sciences) ,  WALLENTIN Lars (Uppsala Clinical Res. Center) ,  THE RE-LY INVESTIGATORS
Material： Circulation Journal  (Circ J)
Volume： 75  Issue： 4  Page： 800-805 (J-STAGE)  Publication year： 2011 
JST Material Number： F0908A  ISSN： 1346-9843  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： *anticoagulant ,...
Semi thesaurus term： サブ解析 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=11A0809644&from=J-GLOBAL&jstjournalNo=F0908A") }}

JST classification (2)： Clinical application of drugs acting on blood and body fluid  (GW14020X) ,  Drug therapy(=pharmacotherapy)for cardiovascular system diseases  (GJ05020M)

Substance index (2)： Dabigatran ,  Warfarin

Reference (14)：

• 1. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). Circulation 2001; 104: 2118-2150.
• 2. Takahashi A, Kuwahara T, Takahashi Y. Complications in the catheter ablation of atrial fibrillation: Incidence and management. Circ J 2009; 73: 221-226.
• 3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
• 4. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A systematic review and meta-analysis. Thromb Res 2006; 118: 321-333.
• 5. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295.

Terms in the title (11)： 心房細動 ,  患者 ,  ダビガトラン ,  ワルファリン ,  有効性 ,  安全性 ,  Re ,  日本人 ,  集団 ,  サブ ,  解析